

	<b>Title/Abstract</b>	<b>Year</b>	<b>Institution</b>
1	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	Northern Respiratory Function Unit Pty Ltd, Jarvis Rd, Elisabeth Vale, SA 5112
2	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	Respiratory Research Foundation Ltd, 57 Fullarton Rd, Kent Town, SA 5065
3	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	Respiratory Research Foundation Ltd, Clinical Trials Centre, 120 Kensington Rd, Toorak Gardens, SA 5065
4	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	Repatriation General Hospital, Department of Respiratory Medicine, Daws Rd, SA 5041
5	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	The Woolcock Institute of Medical research, Glebe Point, NSW 2037
6	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	Australian Clinical Research Network, Maroubra Medical Centre, Anzac Pde, Maroubra, NSW 2035
7	A Phase III, 48-WK, double-blind, randomised, multinational, multicentre, 2-arm parallel group, reference treatment controlled clinical trial of "fixed combination" Belcomethasone Dipropionate plus Formoterol Fumarate Administered via pMDi (CHF 1535 FOSTER) in patients with severe chronic obstructive pulmonary disease.	2010	The Lung Institute of Western Australia, c/o Sir Charles Gairdner Hospital, Nedlands, WA 6009